Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT06643728
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Interventions
Name:
Bimagrumab
Type:
DRUG
Description:
Administered SC
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Bimagrumab Placebo
Type:
DRUG
Description:
Administered SC
Name:
Tirzepatide Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change from Baseline in Body Weight
TimeFrame:
Baseline, Week 24
Description:
Trial Information
NCT ID
NCT06643728
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025